SubQperior Panel Screen

We perform in vivo panel screenings with subQperiorTM tumor models for efficacy testing of new IO drugs on a regular basis.

Screening new test substances on a panel of syngenic tumor models is useful for fast and economic efficacy testing of immune-modulating drugs, either as a single treatment or in combination with immune-checkpoint inhibitors. We offer 8 of our routine models of which clients can choose 6 models for screening, including CT26wt, CloneM3, 4T1, EMT6, MC38-CEA, B16-F10, RENCA, and LL-2. Vehicle and anti-PD1 treatment arms will be provided free of charge.

  • You pay for one group and receive results from three groups
  • Choose 6 out of 8 syngeneic tumor models
  • Executed with our high-performance subQperior tumor models for outstanding reproducible results
MuScreen for in vivo screen to evaluate immune modulating agents

Find out about our options for immunophenotyping to get the most out of your screen here!